Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Elmer Fudd, where is the LABS press release? You are
View:
Post by piduks on Jun 19, 2024 8:38am

Elmer Fudd, where is the LABS press release? You are

useless because Medpharm Labs has a deal with Avicanna to use this technology as well and this patent has a material impact of Medipharm as well.   Elmer, ever hear the saying about udders on a bull? That's you.

Avicanna Announces USPTO Issuance of Patent SEDDS Technology
GlobeNewswireJun 19, 2024 7:30 AM EDT
Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna’s self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of treating neuropathic pain
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the United States Patent and Trademark Office (“ USPTO ”) issuance of the Patent covering Avicanna’s SEDDS oral cannabinoid compositions and methods for treating neuropathic pain.
 
“We are delighted to announce the USPTO’s issuance of the Patent covering our SEDDS drug delivery technology. Research, development, and evaluation of the potential role of cannabinoids in advanced drug delivery systems for therapeutic benefit have been at the core of the Company’s mission since inception. We are appreciative of the work done by our scientists that have brought us to this milestone, and we are excited about the possibilities of further clinical applications for cannabinoid treatments in neuropathic pain and working closely with healthcare providers to support patients in need,” stated Aras Azadian, CEO.
Comment by mdjbrown on Jun 19, 2024 10:07am
piduks, there is no doubt Labs can do a much better job in the promo dept. as I was under the impression AVCN and LABS were working together on the SEDDS technology. Has this relationship changed? https://www.avicanna.com/avicanna-and-medipharm-labs-expand-strategic-manufacturing-agreement-for-avicannas-proprietary-sedds-technology-capsules-for-canadian-and-international-markets/ Albeit, this ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities